Targeting cancer and autoimmune diseases

Our goal is to improve the treatment and the quality of life in patients suffering from life threatening diseases.

Machavert’s Science Approach

We are creating novel drug substances that will take advantage of the unique properties of nature inspired lipids and combine the target areas indicated in the diagram: the anticancer, immune enhancing, and tumor selective drug delivery.


Who we are

Our mission and our goals

Machavert is a bio-pharmaceutical company that develops new, first-in-class therapeutics that will harness the power of the human body to treat cancer and autoimmune diseases. Our approach takes advantage of nature-inspired non-toxic substances that inhibit cancer growth, interact with the human immune system or enhance the targeting and efficacy of other therapeutics.

Our primary goal is to improve the length and the quality of life of patients suffering from life threatening diseases such as pancreatic cancer. Machavert currently focuses on preclinical research and development to build a robust portfolio of drug candidates for clinical trials.

Our drug candidates

Our leading drug candidate, designated as MP1000, is a nanoparticulate liposomal phospholipid immune-modulating agent that exhibits potent anti-cancer efficacy as well as a very low toxicity in animal models. In addition to progressing MP1000 through IND enabling studies and toward human clinical trials, we are developing next generation drug candidates to take advantage of our phospholipid platform in tumor specific drug delivery and immuno-oncology.

Creativity, collaboration and innovation.

At Machavert, we believe that the key to our success is a close collaboration in a creative team.

We are a group of passionate innovators with multidisciplinary expertise; focused on the challenge to create new ways to treat cancer and other diseases with unmet medical needs.

  • Creativity
  • Collaboration
  • Innovation


We have partnered with leading firms to provide us with additional expertise, guidance and resources.

  • Highlighted Partnerships